ALLIANCE PHARMA PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.41 GBX | +3.09% |
|
-0.22% | -0.22% |
| 06-19 | Alliance Pharma pays no dividend as board focus on reinvesting cash | AN |
| 06-19 | Transcript : Alliance Pharma plc, 2023 Earnings Call, Jun 19, 2024 |
Presenter SpeechUnknown Executive (Executives)Good morning, and a very warm welcome to our 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.
Sector
Pharmaceuticals
Calendar
2024-09-23
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.392
GBP
Average target price
0.6243
GBP
Spread / Average Target
+59.26%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.22% | 267M | |
| +19.68% | 43.67B | |
| +26.21% | 22.79B | |
| +20.73% | 15.45B | |
| +17.63% | 14.29B | |
| +52.60% | 12.83B | |
| -0.05% | 6.79B | |
| -11.88% | 6.52B | |
| +12.62% | 5.59B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- APH Stock
- News Alliance Pharma plc
- Transcript : Alliance Pharma plc, 2023 Earnings Call, Jun 19, 2024
